Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vivus Will Cut Population In Qnexa Resubmission

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech announces it will resubmit its obesity drug by the end of October, two months ahead of schedule, after a meeting with FDA.

You may also be interested in...



Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape

New developments for Vivus’ weight loss drug Qnexa may mean that the regulatory environment for obesity treatments could be improving.

Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape

New developments for Vivus’ weight loss drug Qnexa may mean that the regulatory environment for obesity treatments could be improving.

Vivus Resubmits Qnexa, But Limits Its Market Opportunity

The biotech once again submits its application to FDA for its obesity drug, but the upside potential is drastically cut.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS072775

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel